| 000 | 01637 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250517020240.0 | ||
| 264 | 0 | _c20160203 | |
| 008 | 201602s 0 0 eng d | ||
| 022 | _a1744-8301 | ||
| 024 | 7 |
_a10.2217/fon.15.34 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMustacchi, G | |
| 245 | 0 | 0 |
_aObservational study on adjuvant trastuzumab in HER2-positive early breast cancer patients. _h[electronic resource] |
| 260 |
_bFuture oncology (London, England) _c2015 |
||
| 300 |
_a1493-500 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xpharmacology |
| 650 | 0 | 4 |
_aBreast Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aChemotherapy, Adjuvant |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aItaly |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 |
_aReceptor, ErbB-2 _xantagonists & inhibitors |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 |
_aTrastuzumab _xpharmacology |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aPuglisi, F | |
| 700 | 1 | _aMolino, A M | |
| 700 | 1 | _aCrivellari, D | |
| 700 | 1 | _aGhiotto, C | |
| 700 | 1 | _aFerro, A | |
| 700 | 1 | _aBrunello, A | |
| 700 | 1 | _aSaracchini, S | |
| 700 | 1 | _aTurazza, M | |
| 700 | 1 | _aCretella, E | |
| 700 | 1 | _aIop, A | |
| 700 | 1 | _aMalagoli, M | |
| 700 | 1 | _aStefani, M | |
| 773 | 0 |
_tFuture oncology (London, England) _gvol. 11 _gno. 10 _gp. 1493-500 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2217/fon.15.34 _zAvailable from publisher's website |
| 999 |
_c24648992 _d24648992 |
||